OTCMKTS:RLFTF Relief Therapeutics (RLFTF) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free RLFTF Stock Alerts $1.45 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.39▼$1.4550-Day Range$1.32▼$1.9452-Week Range$1.20▼$9.00Volume425 shsAverage Volume2,789 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Relief Therapeutics alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Relief Therapeutics Stock (OTCMKTS:RLFTF)Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. The company also develops RLF-TD011, a hypochlorous acid topical sprayable solution to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. In addition, it develops OLPRUVA, a sodium phenylbutyrate for the treatment of various inborn errors of metabolism, urea cycle disorders, and maple syrup urine disease; APR-OD32, which is in phase 1 for the treatment of patients with phenylketonuria. Relief Therapeutics Holding AG was founded in 2013 and is based in Geneva, Switzerland.Read More RLFTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLFTF Stock News HeadlinesApril 16, 2024 | americanbankingnews.comRelief Therapeutics (OTCMKTS:RLFTF) Trading Down 9%March 5, 2024 | ca.finance.yahoo.comRelief Therapeutics Holding SA (RLFTF)April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.November 22, 2023 | finance.yahoo.comRelief Therapeutics Announces CEO TransitionNovember 15, 2023 | morningstar.comRelief Therapeutics Holding SA RLFTFOctober 10, 2023 | finance.yahoo.comRelief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing MilestoneSeptember 1, 2023 | finance.yahoo.comRelief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 30, 2023 | finance.yahoo.comRelief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer TherapeuticsApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.July 19, 2023 | finanznachrichten.deRelief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec HealthJuly 19, 2023 | finance.yahoo.comRelief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec HealthJune 23, 2023 | finance.yahoo.comRelief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE(R) in the Middle EastJune 23, 2023 | uk.sports.yahoo.comRELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private PlacementJune 20, 2023 | finance.yahoo.comRELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of ShareholdersJune 20, 2023 | finance.yahoo.comRELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of ShareholdersJune 16, 2023 | msn.comRelief Therapeutics announces CHF 5M private placementJune 16, 2023 | finance.yahoo.comRELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private PlacementMay 15, 2023 | finance.yahoo.comRelief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant LaboratoryMay 12, 2023 | finance.yahoo.comRelief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange CommissionMay 3, 2023 | finance.yahoo.comRelief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary SharesApril 5, 2023 | finance.yahoo.comRelief Therapeutics Announces Executive Leadership Team ChangeApril 4, 2023 | finance.yahoo.comRelief Therapeutics Holding SA to Hold Extraordinary General Meeting of ShareholdersApril 3, 2023 | markets.businessinsider.comRelief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory BoardMarch 22, 2023 | finance.yahoo.comRelief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023March 17, 2023 | finance.yahoo.comRelief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual MeetingMarch 16, 2023 | finance.yahoo.comRelief Therapeutics Announces Availability of New PKU GOLIKE BARs in EuropeMarch 15, 2023 | finance.yahoo.comRelief Therapeutics Provides Update From Collaboration Partner on OLPRUVASee More Headlines Receive RLFTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relief Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:RLFTF CUSIPN/A CIK1854078 Webwww.relieftherapeutics.com PhoneN/AFaxN/AEmployees69Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Michelle Lock (Age 56)Interim CEO & Director Comp: $101.31kMr. Jeremy Meinen CPA (Age 35)CFO & Treasurer Mr. Paolo Galfetti (Age 59)Chief Operating Officer Comp: $164.34kKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors RLFTF Stock Analysis - Frequently Asked Questions How have RLFTF shares performed in 2024? Relief Therapeutics' stock was trading at $2.22 at the beginning of the year. Since then, RLFTF stock has decreased by 34.7% and is now trading at $1.45. View the best growth stocks for 2024 here. Are investors shorting Relief Therapeutics? Relief Therapeutics saw a decline in short interest in April. As of April 15th, there was short interest totaling 1,700 shares, a decline of 82.3% from the March 31st total of 9,600 shares. Based on an average daily volume of 4,100 shares, the days-to-cover ratio is currently 0.4 days. View Relief Therapeutics' Short Interest. When did Relief Therapeutics' stock split? Shares of Relief Therapeutics reverse split on the morning of Friday, May 5th 2023. The 1-400 reverse split was announced on Friday, May 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Relief Therapeutics? Shares of RLFTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RLFTF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relief Therapeutics Holding SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
